Subtypes of SNs
| . | PTLD . | AL/MDS . | ST∗ . | . | ||
|---|---|---|---|---|---|---|
| Patients with SNs, n (%) | 145 | 100% | 23 | 100% | 65∗ | 100% |
| Transplant period | ||||||
| 1988-2000 | 8 | 6 | 1 | 5 | 6 | 9 |
| 2001-2005 | 19 | 13 | 8 | 35 | 5 | 8 |
| 2006-2010 | 66 | 45 | 9 | 39 | 35 | 54 |
| 2011-2015 | 46 | 32 | 4 | 17 | 18 | 28 |
| ≥2016 | 6 | 4 | 1 | 4 | 1 | 1 |
| Median age at UCBT, y (range) | 26 | (0.3-68) | 23 | (1-62) | 50 | (0.5-67) |
| Age <18 | 56 | 39 | 10 | 43 | 18 | 28 |
| Age ≥18 | 89 | 61 | 13 | 57 | 47 | 72 |
| Median interval (UCBT-SN), mo (IQR) | 3.7 | (2-7) | 28 | (16-54) | 54 | (30-83) |
| Nonmalignant diseases | 29 | 20 | 2 | 9 | 3 | 5 |
| Malignant diseases | 116 | 80 | 21 | 91 | 62 | 95 |
| MAC | 85 | 59 | 12 | 52 | 29 | 45 |
| TBI | 65 | 45 | 10 | 43 | 43 | 66 |
| ATG | 114 | 79 | 12 | 52 | 31 | 48 |
| Alemtuzumab | 3 | 2 | 3 | 13 | 1 | 2 |
| Recipient EBV-seropositivity | 82 | 57 | 12 | 52 | 34 | 52 |
| Collected TNC at cryopreservation (×107/kg), median (IQR) | 4.5 | 3.5-6.0 | 5.0 | 3.4-7.3 | 5.1 | 4.3-6.4 |
| HLA disparity, n (%) | ||||||
| 0/6 MM | 18 | 12 | 1 | 4 | 8 | 12 |
| 1/6 MM | 55 | 38 | 7 | 30 | 20 | 31 |
| 2/6 MM | 55 | 38 | 9 | 39 | 26 | 40 |
| 3/6 MM | 3 | 2 | 3 | 13 | 1 | 2 |
| Missing | 14 | 10 | 3 | 13 | 10 | 15 |
| Survivors, n | 29 | 7 | 32 | |||
| Median follow-up for survivors after UCBT, mo | 96 | 7-225 | 72 | 29-161 | 125 | 55-292 |
| Median follow-up for survivors after SN, mo | 92 | 5-223 | 35 | 16-110 | 58 | 14-179 |
| . | PTLD . | AL/MDS . | ST∗ . | . | ||
|---|---|---|---|---|---|---|
| Patients with SNs, n (%) | 145 | 100% | 23 | 100% | 65∗ | 100% |
| Transplant period | ||||||
| 1988-2000 | 8 | 6 | 1 | 5 | 6 | 9 |
| 2001-2005 | 19 | 13 | 8 | 35 | 5 | 8 |
| 2006-2010 | 66 | 45 | 9 | 39 | 35 | 54 |
| 2011-2015 | 46 | 32 | 4 | 17 | 18 | 28 |
| ≥2016 | 6 | 4 | 1 | 4 | 1 | 1 |
| Median age at UCBT, y (range) | 26 | (0.3-68) | 23 | (1-62) | 50 | (0.5-67) |
| Age <18 | 56 | 39 | 10 | 43 | 18 | 28 |
| Age ≥18 | 89 | 61 | 13 | 57 | 47 | 72 |
| Median interval (UCBT-SN), mo (IQR) | 3.7 | (2-7) | 28 | (16-54) | 54 | (30-83) |
| Nonmalignant diseases | 29 | 20 | 2 | 9 | 3 | 5 |
| Malignant diseases | 116 | 80 | 21 | 91 | 62 | 95 |
| MAC | 85 | 59 | 12 | 52 | 29 | 45 |
| TBI | 65 | 45 | 10 | 43 | 43 | 66 |
| ATG | 114 | 79 | 12 | 52 | 31 | 48 |
| Alemtuzumab | 3 | 2 | 3 | 13 | 1 | 2 |
| Recipient EBV-seropositivity | 82 | 57 | 12 | 52 | 34 | 52 |
| Collected TNC at cryopreservation (×107/kg), median (IQR) | 4.5 | 3.5-6.0 | 5.0 | 3.4-7.3 | 5.1 | 4.3-6.4 |
| HLA disparity, n (%) | ||||||
| 0/6 MM | 18 | 12 | 1 | 4 | 8 | 12 |
| 1/6 MM | 55 | 38 | 7 | 30 | 20 | 31 |
| 2/6 MM | 55 | 38 | 9 | 39 | 26 | 40 |
| 3/6 MM | 3 | 2 | 3 | 13 | 1 | 2 |
| Missing | 14 | 10 | 3 | 13 | 10 | 15 |
| Survivors, n | 29 | 7 | 32 | |||
| Median follow-up for survivors after UCBT, mo | 96 | 7-225 | 72 | 29-161 | 125 | 55-292 |
| Median follow-up for survivors after SN, mo | 92 | 5-223 | 35 | 16-110 | 58 | 14-179 |
MM, mismatch; TNC, total nucleated cell.
Seven patients developed 2 STs, which corresponded to a total of 72 ST reported.